Last reviewed · How we verify
lisaftoclax +BTK inhibitor
lisaftoclax +BTK inhibitor is a BCL-2 inhibitor + BTK inhibitor combination Small molecule drug developed by Ascentage Pharma Group Inc.. It is currently in Phase 3 development for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Other B-cell malignancies.
Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling.
Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Other B-cell malignancies.
At a glance
| Generic name | lisaftoclax +BTK inhibitor |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | BCL-2 inhibitor + BTK inhibitor combination |
| Target | BCL-2 and BTK (Bruton's tyrosine kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lisaftoclax inhibits BCL-2, an anti-apoptotic protein that allows cancer cells to evade programmed cell death. The BTK inhibitor component blocks Bruton's tyrosine kinase, a key signaling molecule in B-cell receptor pathways that promotes cell survival and proliferation. Together, these agents synergistically induce apoptosis in hematologic malignancies, particularly those dependent on both BCL-2 and BTK signaling.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Other B-cell malignancies
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Infection
- Fatigue
Key clinical trials
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma (PHASE2)
- Global Trial in APG2575 for Patients With CLL/SLL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lisaftoclax +BTK inhibitor CI brief — competitive landscape report
- lisaftoclax +BTK inhibitor updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI
Frequently asked questions about lisaftoclax +BTK inhibitor
What is lisaftoclax +BTK inhibitor?
How does lisaftoclax +BTK inhibitor work?
What is lisaftoclax +BTK inhibitor used for?
Who makes lisaftoclax +BTK inhibitor?
What drug class is lisaftoclax +BTK inhibitor in?
What development phase is lisaftoclax +BTK inhibitor in?
What are the side effects of lisaftoclax +BTK inhibitor?
What does lisaftoclax +BTK inhibitor target?
Related
- Drug class: All BCL-2 inhibitor + BTK inhibitor combination drugs
- Target: All drugs targeting BCL-2 and BTK (Bruton's tyrosine kinase)
- Manufacturer: Ascentage Pharma Group Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic lymphocytic leukemia (CLL)
- Indication: Drugs for Small lymphocytic lymphoma (SLL)
- Indication: Drugs for Other B-cell malignancies
- Compare: lisaftoclax +BTK inhibitor vs similar drugs
- Pricing: lisaftoclax +BTK inhibitor cost, discount & access